| Bioactivity | XMD-17-51 TFA is a pyrimido-diazepinone compound that is able to modulate protein kinases[1]. |
| Invitro | XMD-17-51 TFA is a pyrimido-diazepinone compound that is able to modulate protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK, ULK2, PLK, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and can be used in the treatment of various diseases, disorders or conditions[1]. |
| Name | XMD-17-51 TFA |
| CAS | 2436579-93-8 |
| Formula | C23H25F3N8O3 |
| Molar Mass | 518.49 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. WO 2014145909 A2. [2]. Yang WQ, Zhao WJ, Zhu LL, et al. XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression. Front Pharmacol. 2021;12:603453. |